Baxter International Inc (BAX) : Hendershot Investments reduced its stake in Baxter International Inc by 9.8% during the most recent quarter end. The investment management company now holds a total of 69,091 shares of Baxter International Inc which is valued at $3,338,477 after selling 7,507 shares in Baxter International Inc , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Baxter International Inc makes up approximately 1.65% of Hendershot Investments’s portfolio.
Other Hedge Funds, Including , Canandaigua National Bank Trust Co reduced its stake in BAX by selling 542 shares or 4.45% in the most recent quarter. The Hedge Fund company now holds 11,627 shares of BAX which is valued at $561,817. Baxter International Inc makes up approx 0.16% of Canandaigua National Bank Trust Co’s portfolio.W.g. Shaheen Associates Dba Whitney Co reduced its stake in BAX by selling 7,845 shares or 59.91% in the most recent quarter. The Hedge Fund company now holds 5,250 shares of BAX which is valued at $243,180. Baxter International Inc makes up approx 0.10% of W.g. Shaheen Associates Dba Whitney Co’s portfolio.Charter Trust Co boosted its stake in BAX in the latest quarter, The investment management firm added 126 additional shares and now holds a total of 20,045 shares of Baxter International Inc which is valued at $936,102. Baxter International Inc makes up approx 0.11% of Charter Trust Co’s portfolio. Pioneer Trust Bank N Aor added BAX to its portfolio by purchasing 4,480 company shares during the most recent quarter which is valued at $208,544. Baxter International Inc makes up approx 0.12% of Pioneer Trust Bank N Aor’s portfolio.
Baxter International Inc closed down -0.2 points or -0.41% at $48.02 with 54,89,155 shares getting traded on Friday. Post opening the session at $48.18, the shares hit an intraday low of $47.82 and an intraday high of $48.34 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.
Investors should note that on Jul 19, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Aug 31, 2016 as the ex-dividend date and fixed the record date on Sep 2, 2016. The payable date has been fixed on Oct 3, 2016.
Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.